Health 2.0 Launches CardioEngagement Developer Challenge
September 27, 2011 – Health 2.0 announced the launch of the Novartis CardioEngagement Challenge, asking multi-disciplinary teams of developers to create an interactive solution enabling patients to better manage their cardiovascular health through a customizable, user-friendly interface.
The Novartis challenge is part of a broader, bold new program called the Health 2.0 Developer Challenge; it is designed to spur innovations in the use of technology to improve healthcare outcomes. The Health 2.0 Developer Challenge is a partnership between Health 2.0 and the Office of the National Coordinator for Health Information Technology (ONC), a division of the Department of Health and Human Services.
Novartis Pharmaceuticals Corp. is sponsoring the CardioEngagement Challenge to promote innovation in the area of engagement, support and education for patients with cardiovascular disease.
By taking a more active role in managing their disease, people with cardiovascular disease have the ability to significantly impact half of the risk factors affecting their overall cardiovascular health. Engaging patients is the area both patients and healthcare professionals struggle with most.
Developers are asked to think big when tackling cardiovascular disease, the number one killer in America. In that spirit, all entrants should consider the following areas:
- Health support systems through community and family engagement;
- Improving health education through better patient engagement;
- Risk profiling tools to promote positive behavior and lifestyle changes
- Information sharing with appropriate healthcare stakeholders.
All applications developed for the challenge should leverage existing publicly available data sources (e.g. Healthdata.gov, Health Indicators Warehouse). The competition will favor entries that work across multiple platforms and have the capacity for scalability and easy deployment.
A board of key stakeholders within the healthcare and health technology community will judge entries and select the solution that best addresses the needs of cardiovascular patients everywhere.
Teams will be asked to submit concepts for their applications in a PowerPoint slide deck and optional video presentation. Four finalists will be selected among the submissions and will each receive $15,000 to develop a prototype of their concept. The finalists will then present their prototypes in a live demonstration at the United States headquarters of Novartis.
One winning concept will be selected and the winning team will receive $100,000 to fully develop and launch their concept in the market.
For more information: www.cardioengagement.org
More like this
- HIMSS Submits Comments on Meaningful Use Stage 2 and Standards & Certification Criteria NPRMs
- Novartis Pharmaceuticals
- First Results From Medtronic Engager TAVI Device Demonstrate Positive Outcomes
- Drug Information Association Hosts Conference on Cardiovascular Safety, QT/Arrhythmia Assessment in Drug Development
- CardioMEMS Inc. Wins 2012 Intel Innovation Award